Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
Purpose
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
Condition
- COVID-19
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- • Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between March 2018 and August 2021. - >18 years old
Exclusion Criteria
- • Outpatient visit - Not admitted to an inpatient or observation status
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Recruiting Locations
More Details
- NCT ID
- NCT06334731
- Status
- Completed
- Sponsor
- Methodist Health System
Detailed Description
The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens. Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI) will be higher in the pandemic time period (Pandemic, March 2020 - February 2025) compared to the pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).